Active Ingredient History
Mecasermin rinfabate, also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
22q11 Deletion Syndrome (Phase 2)
Aging (Early Phase 1)
Amyotrophic Lateral Sclerosis (Phase 3)
Anorexia Nervosa (Phase 3)
Autism Spectrum Disorder (Phase 2)
Bone Diseases (Phase 2)
Burns (Phase 2/Phase 3)
Crohn Disease (Phase 2/Phase 3)
Cystic Fibrosis (Phase 1)
Diabetes Mellitus (Phase 3)
Genetic Diseases, Inborn (Phase 2)
Growth and Development (Phase 2)
Growth Disorders (Phase 3)
Growth Hormone (Phase 2)
Heart Failure (Phase 1/Phase 2)
HIV-Associated Lipodystrophy Syndrome (Phase 1)
Hyperinsulinism (Phase 2)
Insulin (Phase 3)
Laron Syndrome (Phase 3)
Multiple Sclerosis (Phase 2)
Muscular Dystrophy, Duchenne (Phase 1/Phase 2)
Myocardial Infarction (Phase 1/Phase 2)
Myotonic Dystrophy (Phase 2)
Noonan Syndrome (Phase 2)
Retinopathy of Prematurity (Phase 2)
Rett Syndrome (Phase 2)
Tendinopathy (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
